Your session is about to expire
← Back to Search
CD19 CAR-T Cells for Leukemia and Lymphoma (MULTIPRAT Trial)
MULTIPRAT Trial Summary
This trial is testing a new treatment for leukemia and lymphoma that uses a combination of two types of blood cells, T cells and antibodies. The hope is that this will be a more effective treatment with fewer side effects than current treatments.
MULTIPRAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMULTIPRAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MULTIPRAT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I (or my guardian) can understand and agree to the study's terms.I am currently on corticosteroids for graft-versus-host disease.I have a small amount of cancer left or it came back after a stem cell transplant.I have B-CLL or NHL with CD19+ and am getting a stem cell transplant from a donor.I have CD19+ B-ALL and am getting a stem cell transplant from a donor.I agree to use effective birth control for 6 months after treatment.My treatment involves a specific immune cell therapy targeting CD19.I have severe symptoms from a transplant complication.I do not have leukemia or lymphoma after my stem cell transplant.My liver and kidney functions are within the required limits, and my hemoglobin is above 8.0.My treatment dose is based on total cell count, not specific cell types.I am able to live with some level of independence.I am currently suffering from a severe infection.
- Group 1: Group A with disease
- Group 2: Group B with disease
- Group 3: Group B without disease
- Group 4: Group A without disease
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have researchers conducted any other experiments involving CD19CAR/virus specific T cells?
"At present, there are 104 separate medical studies examining the efficacy of CD19CAR/virus specific T cells. Of those active trials, 30 have already reached phase 3. Although most research on this topic is conducted in Taichung and Florida, 1087 other clinics across the world are also running similar investigations."
What diseases does CD19CAR/virus specific T cell therapy target?
"To address pain, doctors will often use CD19CAR/virus specific T cells. This medication is also beneficial for ameliorating catarrh, rhinorrhoea, and musculoskeletal discomfort."
How many individuals are being included in the research project?
"At the present moment, enrollment in this trial is closed. It was initially listed on April 1st 2009 and last updated on August 8th 2022. If you are pursuing other trials, 1969 studies for chronic lymphocytic leukemia (CLL) are currently searching for participants as well as 104 CD19CAR/virus specific T cell endeavors."
Is the enrollment period for this research still open?
"At this juncture, the trial is not accepting new patients. It was initially posted on April 1st 2009 and modified most recently on August 8th 2022. If other studies are of interest, there exist 1969 trials recruiting for chronic lymphocytic leukemia (CLL) and 104 clinical tests enrolling participants with CD19CAR/virus specific T cells."
Is the utilization of CD19CAR/virus specific T cells sanctioned by the FDA?
"Our team's assessment of CD19CAR/virus specific T cells' safety ranked it as a 1 since this is only the initial phase of testing, thereby limiting existing evidence for efficacy and security."
Share this study with friends
Copy Link
Messenger